Corrigendum to "The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment" [Lung Cancer 165C (2022) 124-132].

McLean, AEB; Kao, SC; Barnes, DJ; Wong, KKH; Scolyer, RA; Cooper, WA; Kohonen-Corish, MRJ

Corrigendum to "The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment" [Lung Cancer 165C (2022) 124-132].

McLean, AEB Kao, SC Barnes, DJ Wong, KKH Scolyer, RA Cooper, WA Kohonen-Corish, MRJ

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Lung Cancer, 2022, 166, pp. 252
Issue Date:: 2022-04

Closed Access

	Filename	Description	Size
	PIIS0169500222003671.pdf		258.08 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	McLean, AEB
dc.contributor.author	Kao, SC
dc.contributor.author	Barnes, DJ
dc.contributor.author	Wong, KKH
dc.contributor.author	Scolyer, RA
dc.contributor.author	Cooper, WA
dc.contributor.author	Kohonen-Corish, MRJ
dc.date.accessioned	2022-08-17T01:02:20Z
dc.date.available	2022-08-17T01:02:20Z
dc.date.issued	2022-04
dc.identifier.citation	Lung Cancer, 2022, 166, pp. 252
dc.identifier.issn	0169-5002
dc.identifier.issn	1872-8332
dc.identifier.uri	http://hdl.handle.net/10453/160402
dc.description.abstract	The authors regret that the following disclosures were not published. RAS has received fees for professional services from F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Lung Cancer
dc.relation.isbasedon	10.1016/j.lungcan.2022.02.011
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences, 1112 Oncology and Carcinogenesis
dc.subject.classification	Oncology & Carcinogenesis
dc.title	Corrigendum to "The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment" [Lung Cancer 165C (2022) 124-132].
dc.type	Journal Article
utslib.citation.volume	166
utslib.location.activity	Ireland
utslib.for	1103 Clinical Sciences
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
utslib.copyright.status	closed_access	*
dc.date.updated	2022-08-17T01:02:19Z
pubs.publication-status	Published
pubs.volume	166

Abstract:

The authors regret that the following disclosures were not published. RAS has received fees for professional services from F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/160402